GlassScriptPhysician profile
Christi A Witherspoon
NPI 1003860982
$6,232.10
in general payments reported to CMS, 2019-2025
30 companies · $77.34 in 2025
The $77.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $944 · 2021: $1,192 · 2022: $1,222 · 2023: $1,322 · 2024: $602 · 2025: $77.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,097.74 | 2019-2024 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $711.30 | 2019-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $582.58 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $467.95 | 2020-2023 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $420.51 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $394.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $374.45 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $355.36 | 2021 | |
| Esperion Therapeutics, INC. | $283.53 | 2020-2021 | |
| Amgen INC. | $229.21 | 2019-2020 | |
| Pfizer INC. | $208.32 | 2019-2024 | |
| Amarin Pharma, INC. | $192.92 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $143.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.18 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.38 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $80.95 | 2019-2024 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $60.71 | 2022 | |
| Merck Sharp & Dohme LLC | $55.59 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Arbor Pharmaceuticals, INC. | $52.86 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $43.00 | 2023 | Edarbi |
| Ethicon INC. | $36.63 | 2024 | Monarch Platform |
| Kowa Pharmaceuticals America, INC. | $31.80 | 2019-2022 | |
| Gilead Sciences, INC. | $25.12 | 2019 | |
| Exact Sciences Corporation | $22.86 | 2023 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $20.49 | 2021 | |
| Allergan, INC. | $19.25 | 2020 | |
| Genzyme Corporation | $19.01 | 2019 | |
| Shield Therapeutics INC | $16.09 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $14.78 | 2020 | |
| Endogastric Solutions, INC | $9.58 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christi Witherspoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.